Aptose Biosciences’ (APTO) “Buy” Rating Reiterated at HC Wainwright

Aptose Biosciences (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $2.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com initiated coverage on shares of Aptose Biosciences in a report on Wednesday. They issued a “hold” rating on the stock.

Aptose Biosciences Stock Performance

NASDAQ:APTO opened at $0.21 on Friday. Aptose Biosciences has a fifty-two week low of $0.13 and a fifty-two week high of $2.60. The firm has a market cap of $12.83 million, a PE ratio of -0.07 and a beta of 0.87. The business has a 50 day moving average price of $0.25 and a 200-day moving average price of $0.41.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent quarter. Institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.